SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.__)

	I by the Registrant $oxin $ Filed by a Party other than the Registrant $oxin $
Chec	ck the appropriate box:
	Preliminary Proxy Statement
	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
	Definitive Proxy Statement
\times	Definitive Additional Materials
	Soliciting Material Pursuant to § 240.14a-12
	X4 Pharmaceuticals, Inc.
	(Name of Registrant as Specified In Its Charter)
	(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)
Payn	nent of filing Fee (Check the appropriate box):
\times	No fee required.
	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
Title	of each class of securities to which transaction applies:
Agg	regate number of securities to which transaction applies:
	unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is ulated and state how it was determined):
Prop	osed maximum aggregate value of transaction:
Tota	l fee paid:
	Fee paid previously with preliminary materials.
	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid
	previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
Amo	ount Previously Paid:
Forn	n, Schedule or Registration Statement No.:
Filin	g Party:
Date	Filed:





D52170-P49510

You invested in X4 PHARMACEUTICALS, INC. and it's time to vote!

You have the right to vote on proposals being presented at the Annual Meeting. THIS IS AN IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIAL FOR THE STOCKHOLDER MEETING TO BE HELD ON JUNE 2, 2021.

Get informed before you vote

View the Notice, Proxy Statement and Form of Proxy, and Annual Report online at www.proxyvote.com OR you can receive a free paper or email copy of the material(s) by requesting prior to May 19, 2021. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



For complete information and to vote, visit www.ProxyVote.com

Control #

Smartphone users

Point your camera here and vote without entering a control number





How to Vote

During the meeting* - You may vote by attending the meeting via the Internet at www.virtualshareholdermeeting.com/XFOR2021 and vote during the meeting using the control number indicated in this notice.

Other voting options — You may also vote by Internet (by visiting www.ProxyVote.com or scanning the QR Barcode shown to the left), or by phone or mail (by requesting a paper copy of the proxy materials, which will include a proxy card with additional voting instructions). Vote by 11:59 P.M. ET on June 1, 2021, Have the control number indicated in this notice when voting by Internet or by phone.

^{*}Please check the meeting materials for any special requirements for meeting attendance.

THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters.

You are receiving this communication because you hold shares in X4 Pharmaceuticals, Inc.

This communication presents only an overview of the more complete proxy materials, which contain important information and are available to you on the Internet or by mail. We encourage you to access and review all of the important information contained in the proxy materials before voting.

See the reverse side of this notice to obtain proxy materials and voting instructions.

Vot	ting Items	Recommend
1.	To elect three (3) nominees, David McGirr, M.B.A., Paula Ragan, Ph.D. and Michael S. Wyzga, to the Board of Directors to hold office until the 2024 Annual Meeting of Stockholders and until their successors are duly elected and qualified. Nominees: 01) David McGirr, M.B.A. 02) Paula S. Ragan, Ph.D. 03) Michael S. Wyzga	For
2.	To ratify the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2021.	⊘ For

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Sign up for E-delivery".